|Dr. Angelos M. Stergiou M.D., ScD h.c.||Founder, Pres, CEO & Director||827.57k||N/A||1976|
|Ms. Barbara A. Wood||Exec. VP, Gen. Counsel & Sec.||577.29k||N/A||1963|
|Dr. Dragan Cicic||Sr. VP of Clinical Devel.||435.43k||N/A||1963|
|Mr. John Thomas Burns CPA, CPA||VP of Fin., Corp. Controller & Chief Accounting Officer||N/A||N/A||1985|
|Mr. Martin G. Baum||Chief Operating Officer||N/A||N/A||1966|
|Dr. Christopher R. Shackleton||Director of Clinical and Bus. Operations||N/A||N/A||N/A|
|Mr. JÃ¶rg W. Breitkopf||Head of Clinical Operations||N/A||N/A||N/A|
|Mr. David D. Moser||VP of Legal Affairs||N/A||N/A||N/A|
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.
SELLAS Life Sciences Group, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.